Aims
This review aimed to identify studies of QOL in constipation and to compare these results with other chronic conditions
Methods
A comprehensive literature search identified studies in constipation that used a generic QOL tool. Results were statistically pooled where possible, and compared to published results using the same tools in other chronic conditions.
Results
13 qualifying studies were identified, 10 in adults and 3 in children. Results from 8 studies using the SF-36/12 tools were pooled; the remaining 5 were narratively reported. Mental and physical components of QOL scores were consistently impaired in both adult and child populations, with greatest impact being seen in secondary care studies. Mental health effects predominated over physical domains. The magnitude of impact was comparable to that seen in patients with allergies, musculoskeletal conditions and inflammatory bowel disease.
Conclusion
The impact of constipation on QOL is significant and comparable to other common chronic conditions. Improving management may prove offer an effective way of improving QOL for a substantial number of patients. 
Background
Chronic functional constipation is a common condition, with around 15-17% of adults [1, 2] reporting symptoms consistent with the Rome I or II diagnostic criteria. Studies in children yield considerable variation in prevalence estimates, with a range of estimates from 1% -30% (median 10.4%) being identified in the literature [3] . Although rarely associated with life-threatening complications, the impact of constipation on sufferers may be considerable: a recent review [4] identified a growing evidence base that these patients have significantly impaired health related quality of life (HRQoL) compared to unaffected populations, as assessed by objective questionnaires.
Measurement of HRQoL requires the application of an objective and reproducible series of measures, in order to characterise physical, mental, social and functional aspects of an individual's life. The information this yields may be used to inform individual patient management [5] or, more commonly, to provide insight into the typical impact of one or more related conditions within a defined group of patients [6] . More challenging to achieve, but potentially more useful, is the comparison of HRQoL across several unrelated conditions [7] . This process is not only clinically valuable, but also increasingly underlies the decision making process for resource allocations within health care systems.
Meaningful comparison of HRQoL across differing disease areas requires careful selection of the assessment tool to be used. Many of the questionnaires used in quality of life research are specific to individual diseases, or groups of diseases. For example, when considering constipation, one may choose to investigate using a very specific tool, such as the Patient Assessment of Constipation -Quality of Life (PAC-QOL) questionnaire [8] , which has been shown to be internally consistent, reproducible, valid, and responsive to improvements over time. This makes the tool especially valuable for tracking individual patients longitudinally, but of limited value when comparing a group of patients with constipation with a similar group with irritable bowel syndrome. In this circumstance, a broader tool such as the Elderly Bowel Symptom Questionnaire (EBSQ) would be more appropriate [9] . However, if the intention is to compare the impact of constipation with a nongastrointestinal problem, then neither of these approaches would be helpful.
In this circumstance, a generic HRQoL tools is required -some of the most commonly used being the Short Form 36 version 2 (SF-36v2) [10] , the Health Utilities Index mark 3 (HUI3) [11] or the EuroQol 5D (EQ-5D) [12] .
These generic tools are relatively insensitive to specific clinical issues in any given medical condition and are therefore not ideal for following up individual patients. Their strength, however, lies in their ability to detect the global impact of illness and/or disability on a multidimensional construct of psychological, social and physical aspects of quality of life. For this reason, they are ideally placed to give meaning to questions on the relative impact of disparate diseases on HRQoL.
Aims
The aim of this review was to identify published studies that used generic
HRQoL tools in the field of adult or child constipation; to extract data allowing a rational assessment of the impact of constipation on quality of life; to pool these results where appropriate and to carry out a narrative review otherwise;
to compare these results to those arrived at using the same tools in other chronic, non life-threatening conditions.
Methods

Literature Search
A primary search for quality of life studies was carried out in PubMed, using the following terms:
AND
Quality-of-life [MeSH] OR HRQL [TW] OR HRQOL [TW]
Additional electronic searches using similar strategies were carried out using EMBASE and Cochrane Library. Studies were appraised to determine whether they complied with the following inclusion criteria:
• Study applying a generic HRQOL tool to patients with constipation
• Patients with diagnosis of constipation consistent with Rome II/III criteria
• Detailed results of HRQOL scores presented in the paper
• Reference to healthy comparator group scores in the paper Studies were specifically excluded if:
• Only disease-specific assessment tools were used
• Constipation was secondary to other diagnoses
• The study had not been fully published in a peer-reviewed journal
No limitations were placed on language of publication or age of participants
Data extraction and analysis
In studies which used the SF-36 or SF-36v2 tools, mean scores for each of the eight domains were extracted (see table 1 ). These were transformed into norm-based scores, using appropriate national reference values [13] [14] [15] [16] .
Norm-based scoring standardises the raw results for each domain to a consistent scale with mean of 50 and standard deviation of 10 when applied to a healthy population. This allows cross-comparisons between domains [13] .
These eight results were then aggregated using published weighting factors to yield two composite scores for each study -the Physical Component Score (PCS) and the Mental Component Score (MCS). This facilitates the comparison of results across disease entities [13] . In addition to calculating these values for each study and patient group individually, we also calculated a mean value for all studies combined. This mean value included results from one study carried out using the SF-12. This comprises a subset of the SF-36 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w 6 that yields the same two composite measures (PCS + MCS). This is scored using the same normalizing metric as the SF-36, which therefore allows meaningful inclusion of these results into the pooled estimates of MCS and PCS [13] .
In addition to the results for the total dataset, pooled values were also separately estimated for community-based and hospital-based studies.
As most studies did not supply figures for standard deviations, we were unable to undertake a formal random effects meta-analysis and these mean estimates were simply derived by study-size weighting. Equally, the absence of variance data from individual studies precluded the significance testing for differences in aggregate PCS and MCS scores for constipated and healthy populations.
For studies that did not use SF-36, data on comparative scores for each patient group were extracted from the text and used to inform a narrative review.
Results
The primary PubMed search yielded 174 hits, of which 13 fulfilled the inclusion criteria [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] (see figure 1 ). Subsidiary searches identified one additional study [6] .
10 studies were carried out in adult populations: 7 using SF-36 [17] [18] [19] [20] [21] [22] [23] , 1 using SF-12 [6] and two using the Psychological General Well Being index (PGWB) [24, 25] . None used the EQ-5D or HUI3. Three studies were carried out in children, two using the Pediatric Quality of Life Inventory (PedsQL) [26, 27] and one using the Child Health Questionnaire -Parent Form 50
(CHQ-PF50) [28] (table 1) .
Studies using SF-36/SF-12
The studies using SF-36 [17] [18] [19] [20] [21] [22] [23] yielded scores for each of the eight domains tested that were, with few exceptions, significantly lower in individuals with figure 3 ).
All studies
• Mean normalized scores for constipated patients: PCS = 47.5, MCS = 45.8.
• Mean normalized scores for healthy controls: PCS = 51.3, MCS = 48.8.
• • Mean normalized scores for healthy controls: PCS = 51.3, MCS = 49.2.
Hospital based studies
• Mean normalized scores for constipated patients: PCS = 41.9, MCS = 43.9.
• Mean normalized scores for healthy controls: PCS = 50.5, MCS = 48.4.
Studies using PGWB
Two studies carried out in Swedish populations used the PGWP [24, 25] . This index evaluates HRQoL across six domains -anxiety, depressed mood, In the first study [24] 
Paediatric studies
Three studies were identified that evaluated quality of life in children with constipation, all carried out in a hospital setting; two used the PedsQL [26, 27] and one the CHQ-PF50 [28] .
The PedsQL is a generic questionnaire that is completed by both children and their parent and has been validated in patients aged 5 and over. It encompasses physical, emotional, social and school functioning domains, which are then aggregated to yield an overall score ranging from 0-100.
Parental and child scores are separately recorded. In the first study [26] , carried out in the USA, 178 children (age 5-18) referred to a paediatric gastroenterology department and 42 healthy controls attending primary care for routine checks or minor problems were screened using the PedsQL. In the patient group, 80 had constipation, 42 In the second study [27] , carried out in Australia, PedsQL scores for 51 children (aged 8-18) attending surgical and gastrointestinal clinics in for chronic slow transit constipation were compared with 79 healthy controls recruited from a Scout jamboree. Total quality of life scores in children with constipation were significantly lower than those of controls (children 72.9 vs 86.0; p<0.0001; parents 64.4 vs 84.3; p<0.0001). Although decreases in both physical and psychosocial domains were reported, psychosocial factors were impacted to a greater extent. As in the previous study, mean parental scores were lower than those reported by children for the constipated group, although no such difference was observed in the control group.
The reported results of this study correlate well with those of the other study using PedsQL, both in magnitude and trend:
Constipated children:
• Mean child score: 72.9 vs 70.4 in Youssef et al [26] • Mean parent score: 64.4 vs 60.6 in Youssef et al [26] Healthy controls: • Mean parent score: 84.3 vs 80.7 in Youssef et al [26] The third paediatric study [28] respectively. The difference is quoted as statistically significant, although no p-value is given. Subanalysis across the three diagnostic subgroups showed no significant differences, although the physical component for children with non-retentive fecal incontinence was numerically lower than for the other diagnoses.
Discussion
Main results
Our literature search identified an extensive evidence base relating to the QoL impact of chronic constipation using a range of validated questionnaires. The results of these studies demonstrated a consistent effect of constipation on both mental and physical components of quality of life. Amongst population recruited within secondary care, the magnitude of QoL impairment was substantially greater across all domains than that seen in community-recruited cohorts, reflected the more intractable nature of the problem in these patients.
This different was most marked in the mental and emotional aspect of the scores. The generic tools identified in these studies have also been used in other disease areas. The SF36 has been extensively used. Table 2 compares the results of our analysis with those from both a US community reference population with a range of chronic diseases and results of individual hospitalbased studies [29] [30] [31] [32] [33] . The scores found in community studies were comparable to those seen with chronic allergies, dermatitis, diabetes and stable ulcerative colitis, whilst the scores seen in hospital studies were similar to those found in patients with unstable inflammatory bowel disease, functional dyspepsia and a range of chronic rheumatological conditions. Similarly, the PGWB studies yielded scores at least as severe as those seen in untreated peptic ulcer [34] , GORD [35] and patients with mild asthma [36] .
As reported above, in one of the paediatric studies, the scores achieved in the PedsQL were worse for children with constipation than those with GERD and inflammatory bowel disease [26] . The paediatric data are of interest in that they provide a measure of the impact of constipation on the patients' families.
As judged by the ratios of QoL of children with constipation, their parents and controls, there was a greater impact on the parental QoL (ratios 0.75-0.76 vs controls) than children (ratios 0.80-0.85 vs controls) When set against results from other disease are, the QoL impact of constipation is seen to be comparable to results obtained from children attending hospital for a wide range of chronic conditions [5, 37, 38] (table 3) .
Interpretation of the data in tables 2 and 3 requires a degree of caution, as the exact extent to which a generic tool captures the impact of an individual disease on quality of life may vary. Nonetheless, it is probably reasonable to conclude that the impact of constipation is at least comparable to that seen across a wide range of conditions that might normally be considered more "serious". The threshold for diagnosis of constipation varies substantially between patients and doctors and also to some extent between individual clinicians [39] . These studies show, however, that regardless of the criteria used the impact on patients' perceived quality of life is significant and comparable to that seen with other more recognised causes of impaired health.
Clinical relevance
In a US survey of 557 constipation patients of all ages [40] , 52% reported an impact on quality of life, while 69% reported that constipation affected their performance at work or at school. 12% reported that constipation had resulted in absence from work or school in the preceding month, with a mean nonattendance period of 2.4 days. This figure relates to a selected subgroup of patients; however, amongst constipated patients as a whole it been estimated that a mean period of work absence of 0.4 days per year will be seen, equating to 13.7 million days of restricted activity annually in the USA [41] .
The extent to which the results of this study reflect the impact of constipation per se, rather than associated symptoms such as abdominal pain is difficult to ascertain. Examination of the detailed results of the SF-36 studies (figure 2) does not suggest that pain is a major driver of the results, with emotional and mental factors seeming to be of greater importance. In the PGWB studies, the reduction in score was uniform across all domains (data not shown) with no evidence of physical parameters dominating. Similar results were seen in the paediatric PedsQL studies (figure 4). In one study [26] scores were explicitly assessed for those with and without abdominal pain: no significant difference was seen. A contrary result was seen in the Brazilian CHQ-PF50 study, where there was a bias towards physical components, with General Global Health and Bodily Pain & Discomfort being particularly affected.
To some extent, this distinction is moot, as constipation constitutes a combination of symptoms that will vary from one patient to anotherattempting to distinguish the impact of the individual components has the potential to distract from the more general impact of the syndrome as a whole. [42] [43] [44] [45] . These studies do not necessarily relate to therapies in common use and there are none that have been carried out in children. However, whilst there is a clear need to carry out further studies in this area, the apparent impact of treatment on QoL, coupled with the generally low cost of medication, suggest that this is likely to be a cost-effective intervention.
Study limitations
In common with all systematic reviews of the literature, our results are potentially subject to selection bias. Whilst we made every effort to include all published studies in the field, we were obviously unaware of data that was not in the public domain.
Secondly, the studies identified were carried out in populations of differing ages and geographical locations and the diagnosis of chronic constipation was not always made according to consistent criteria. Traditionally one would deal with this kind of between-studies variation by carrying out a random effects pooling -in this analysis, however, there was insufficient information given in the published papers to allow this to be carried out. Consequently, our aggregate assessment of the SF-36 score was carried out using a simple study-size weighting method. It is therefore possible that our pooled result gives undue weight to individual studies with wide between-subjects variation.
Amongst the community-based SF-36 studies one paper [17] was considerably larger than all the others and therefore had the major influence on the estimate of pooled effect. However, this study was carried out to a high standard in seven centres in different countries and yielded results that were comparable to those seen in the smaller studies. Although we were unable to formally assess heterogeneity owing to the lack of variance data, we believe the potential for this study to bias our result was low.
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Competing interests
Page 24 of 31 Alimentary Pharmacology & Therapeutic
• Class I: No limitation of activities; no symptoms from ordinary activities.
• Class II: Mild limitation of activity; comfortable at rest or with mild exertion.
• Class III: Marked limitation of activity; comfortable only at rest.
• Class IV: Severe limitation of activity; symptomatic at rest n/a
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